Iatrogenesis is harm that originates directly from medical care -- from the Greek iatros (physician) and genesis (origin). It encompasses everything from a single adverse drug reaction to population-scale catastrophes like the opioid epidemic. In an era when healthcare spending in the United States alone exceeds $4.5 trillion annually (Centers for Medicare and Medicaid Services, 2023), understanding how the system designed to heal us can also hurt us is not an academic exercise. It is one of the most consequential questions in modern public health.

The concept matters because medicine operates under an implicit social contract: patients surrender autonomy, submit to procedures, and absorb costs on the assumption that they will be better off for it. When that assumption fails systematically -- when the treatment itself becomes a source of suffering -- the breach is not merely clinical. It is moral.

"The medical establishment has become a major threat to health." -- Ivan Illich, Medical Nemesis (1976)

That sentence, written nearly fifty years ago by a philosopher with no medical degree, remains one of the most provocative claims in healthcare literature. It was hyperbolic then, and aspects of it remain contested now. But the evidence assembled since Illich wrote it has only strengthened the core observation: iatrogenic harm is vast, structurally incentivized, and chronically underreported.

The Three Layers of Iatrogenesis: Illich's Framework

Ivan Illich, the Austrian-born social critic and Catholic priest, published Medical Nemesis: The Expropriation of Health in 1976. The book was a polemic, but its analytical framework has proven durable. Illich identified three distinct layers of iatrogenesis, each operating at a different level of society.

Clinical Iatrogenesis

Clinical iatrogenesis is the most visible form: direct physical harm caused by medical treatment. This includes adverse drug reactions, surgical complications, hospital-acquired infections, diagnostic errors, and the cumulative physical damage of overtreatment. A patient who enters the hospital with pneumonia and acquires a methicillin-resistant Staphylococcus aureus (MRSA) infection during their stay has experienced clinical iatrogenesis. A woman who undergoes a thyroidectomy for a cancer that would never have progressed has experienced it. A teenager prescribed OxyContin for a sports injury who develops opioid dependence has experienced it.

Clinical iatrogenesis is the category that the medical profession has been most willing to acknowledge and address, in part because it lends itself to measurement and quality improvement. Hospital safety protocols, adverse event reporting systems, and surgical checklists all target clinical iatrogenesis specifically.

Social Iatrogenesis

Social iatrogenesis is the process by which medicine absorbs experiences that were previously managed through social, cultural, or personal resources and redefines them as medical conditions requiring professional intervention. Childbirth becomes a hospital procedure. Grief becomes prolonged grief disorder (added to the DSM-5-TR in 2022). Shyness becomes social anxiety disorder. The natural cognitive decline of aging becomes mild cognitive impairment requiring pharmaceutical management.

Illich argued that this process does not merely expand medicine's domain -- it actively weakens the social structures and personal capacities that previously helped people navigate difficulty. When a community's elders once helped the bereaved process loss, and that function is transferred to psychiatrists prescribing sertraline, something has changed that is not captured in a clinical outcomes measure.

The counterargument is real: many conditions that were previously dismissed as "just part of life" -- postpartum depression, PTSD, ADHD -- cause genuine suffering that responds to treatment. The line between legitimate medical recognition and pathologization of normal experience is genuinely difficult to draw. But the pattern Illich identified -- the steady expansion of medical authority into domains where it may not be the best or only answer -- is documented in the sociological literature and continues to accelerate.

Structural Iatrogenesis

Structural iatrogenesis, Illich's deepest category, describes the erosion of the human capacity for self-care, pain tolerance, and acceptance of mortality. A society that has delegated all health decisions to professionals loses something that Illich considered irreplaceable: the ability of individuals and communities to manage their own well-being.

The concept finds a modern echo in what physicians now call "health literacy" problems -- patients who cannot interpret basic health information, who defer entirely to clinical authority, and who lack the self-efficacy to manage chronic conditions. The irony Illich would have noted: the medical system's proposed solution to structural iatrogenesis is more medical intervention, in the form of health education programs and patient engagement platforms.

Level of Iatrogenesis	Definition	Modern Examples
Clinical	Direct physical harm from medical care	Adverse drug reactions, surgical errors, hospital infections, overtreatment side effects
Social	Medicalization of normal human experience	Grief classified as psychiatric disorder, normal aging treated pharmacologically, childbirth as surgical event
Structural	Erosion of personal and community capacity for self-care	Health illiteracy, dependence on medical authority for routine decisions, loss of cultural practices for managing pain and death

The Scale of Clinical Iatrogenesis: What the Numbers Show

How many people does medicine harm each year? The honest answer is that no one knows precisely, because healthcare systems have historically been reluctant to systematically measure their own errors. But the estimates that do exist are staggering.

The landmark 1999 report by the U.S. Institute of Medicine, To Err is Human, estimated that between 44,000 and 98,000 Americans die annually from preventable medical errors in hospitals. At the time, these figures placed medical error alongside motor vehicle accidents and breast cancer as leading causes of death. The report catalyzed a patient safety movement that continues today.

In 2013, John T. James published a systematic review in the Journal of Patient Safety that revised the estimate dramatically upward. Using a weighted analysis of four studies that employed the Global Trigger Tool methodology (a more sensitive detection method than voluntary reporting), James estimated that between 210,000 and 440,000 patients die each year in U.S. hospitals from preventable harm. If accurate, that figure would make medical error the third leading cause of death in the United States, behind only heart disease and cancer.

A 2016 analysis by Martin Makary and Michael Daniel at Johns Hopkins, published in the BMJ, reached a similar conclusion. Using hospital admission data and applying published adverse event rates, they estimated over 250,000 deaths per year from medical error in the U.S. -- and emphasized that death certificates do not include a category for medical error, making the problem structurally invisible in official mortality statistics.

Source	Year	Estimated Annual Preventable Deaths (U.S.)	Methodology
Institute of Medicine, To Err is Human	1999	44,000-98,000	Chart review extrapolation
James, Journal of Patient Safety	2013	210,000-440,000	Global Trigger Tool meta-analysis
Makary & Daniel, BMJ	2016	251,000+	Admission-rate modeling
CDC estimate of hospital-acquired infections	Ongoing	~99,000 deaths from 1.7 million HAIs	National surveillance data
FDA adverse drug event reports	Ongoing	~100,000 deaths; 700,000+ hospitalizations	Voluntary reporting (likely undercount)

These numbers should be interpreted with care. Defining "preventable" is genuinely difficult in complex clinical settings where patients are already seriously ill. Some researchers argue these estimates are inflated by attribution problems -- ascribing death to medical error in patients who would have died regardless. Others argue they are undercounts, because voluntary reporting systems capture only a fraction of actual adverse events. The Agency for Healthcare Research and Quality (AHRQ) estimates that only 10-20% of medical errors are ever reported.

The scale, regardless of the precise number, is undeniable and demands explanation.

The Opioid Crisis: Iatrogenesis at Population Scale

No modern example illustrates iatrogenesis more devastatingly than the American opioid epidemic. It is a textbook case of the cobra effect in healthcare: a well-intentioned medical intervention that created a catastrophe far larger than the problem it aimed to solve.

The Origins of a Catastrophe

In the late 1980s and 1990s, a genuine problem drove a dangerous overcorrection. Pain was systematically undertreated in American medicine. Studies documented that patients -- particularly minorities and the elderly -- suffered needlessly because physicians were excessively cautious about prescribing analgesics. Pain advocacy organizations, supported by pharmaceutical companies, pushed for a cultural shift.

In 1996, the American Pain Society introduced the concept of pain as "the fifth vital sign," recommending that pain be assessed and documented at every clinical encounter. The Joint Commission (which accredits hospitals) incorporated pain management standards that created institutional pressure to treat pain aggressively.

Into this environment, Purdue Pharma launched OxyContin in 1996 with an extraordinary marketing claim: that its extended-release formulation carried an addiction risk of "less than 1%." This figure, derived from a one-paragraph letter to the New England Journal of Medicine by Hershel Jick and Jane Porter (1980) about hospitalized patients receiving short-term opioids, was extrapolated far beyond its original context and applied to chronic outpatient prescribing where it had no evidentiary basis.

Internal documents revealed through subsequent litigation showed that Purdue executives knew that OxyContin's addiction risk was significantly higher than their marketing materials suggested, and that the drug's 12-hour pain relief often wore off in 8 hours, leading patients to dose more frequently and develop tolerance faster. In 2007, Purdue pleaded guilty to federal charges of misbranding OxyContin and paid $634 million in fines. In 2020, Purdue pleaded guilty again, this time to charges including conspiracy to defraud the United States, with penalties exceeding $8 billion.

The Cascade

The iatrogenic cascade unfolded in predictable stages:

Stage 1 -- Prescription surge: Between 1991 and 2011, opioid prescriptions in the United States nearly tripled, from 76 million to 219 million annually. The U.S., with 4.4% of the global population, consumed approximately 80% of the global opioid supply.

Stage 2 -- Dependence: Patients prescribed opioids for chronic pain developed physical dependence. Many progressed to opioid use disorder. Some began obtaining pills outside legitimate prescriptions -- from multiple physicians, from the illicit market, or by diverting family members' prescriptions.

Stage 3 -- Heroin transition: When prescribing restrictions tightened in the early 2010s, many people dependent on prescription opioids switched to heroin, which was cheaper and more readily available. The DEA documented a direct correlation between OxyContin reformulation (which made pills harder to crush and snort) and surging heroin use.

Stage 4 -- Fentanyl contamination: When the illicit heroin supply became contaminated with illicitly manufactured fentanyl -- a synthetic opioid 50 to 100 times more potent than morphine -- overdose deaths surged to unprecedented levels.

"The opioid epidemic was not a failure of individual willpower. It was a failure of a system that created mass dependence through the prescription pad and then abandoned the people it had made dependent." -- Dr. Anna Lembke, Chief of the Stanford Addiction Medicine Dual Diagnosis Clinic, Drug Dealer, MD (2016)

The cumulative death toll from opioid overdoses in the United States surpassed 500,000 between 1999 and 2020, according to the Centers for Disease Control and Prevention. In 2021 alone, more than 80,000 Americans died from opioid overdoses -- more than the total U.S. combat deaths in the Vietnam War. The economic cost has been estimated at over $1 trillion annually when accounting for healthcare, criminal justice, lost productivity, and premature death (Council of Economic Advisers, 2017).

Antibiotic Resistance: The Slow-Moving Iatrogenic Catastrophe

If the opioid crisis represents iatrogenesis at acute, visible scale, antibiotic resistance represents something perhaps more dangerous: iatrogenesis that accumulates silently over decades until it threatens the foundations of modern medicine itself.

Antibiotics are among the most transformative innovations in medical history. Before their widespread availability in the 1940s, a scratch that became infected could kill. Surgical procedures carried enormous mortality risk. Organ transplants and chemotherapy -- both of which severely compromise immune defenses -- were unthinkable without antibiotics to manage opportunistic infections.

The iatrogenic problem is that widespread antibiotic use has accelerated the evolution of resistant bacteria. This is not a side effect of misuse alone -- it is a direct, predictable consequence of the mechanism by which antibiotics work. When an antibiotic kills susceptible bacteria in a population, any resistant mutants survive and reproduce. The broader and more frequent the antibiotic use, the stronger the selective pressure favoring resistance.

The Scope of the Threat

The World Health Organization has declared antimicrobial resistance one of the top ten global public health threats. A landmark 2022 study published in The Lancet (Murray et al.) estimated that bacterial antimicrobial resistance was directly responsible for 1.27 million deaths globally in 2019 and contributed to 4.95 million deaths -- making it a larger killer than HIV/AIDS or malaria.

The O'Neill Review on Antimicrobial Resistance (2016), commissioned by the UK government, projected that on current trends, drug-resistant infections would kill 10 million people per year by 2050 -- more than cancer currently kills -- and cost the global economy $100 trillion in cumulative lost output.

Key resistant organisms include methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant Enterobacteriaceae (CRE), extensively drug-resistant tuberculosis (XDR-TB), and vancomycin-resistant Enterococcus (VRE). For some of these organisms, the treatment pipeline is nearly empty: physicians are resorting to colistin, an antibiotic abandoned decades ago due to kidney toxicity, as a last-resort treatment -- and colistin resistance is now emerging.

The cruel feedback loop: antibiotics prescribed to treat infections are creating the conditions for future infections that cannot be treated. The cure manufactures the next disease.

Overdiagnosis: The Quiet Epidemic of Finding Too Much

A subtler form of iatrogenesis has attracted growing attention in medical literature: overdiagnosis -- the detection, through screening or testing, of conditions that would never have caused symptoms, harm, or death in the patient's lifetime.

Overdiagnosis is not the same as misdiagnosis (getting the diagnosis wrong) or false positives (test results that are later shown to be incorrect). In overdiagnosis, the diagnosis is technically accurate -- the cells under the microscope really are cancerous, the scan really does show a nodule. The problem is that many of these findings represent indolent disease that would never progress, never spread, and never kill. But once detected, they are almost always treated.

The South Korean Thyroid Cancer Epidemic

The most striking case study comes from South Korea. In 1999, the country launched a nationwide cancer screening program. Although thyroid screening was not part of the official program, the infrastructure made thyroid ultrasound readily available, and physicians began offering it as an add-on. The result was extraordinary: the incidence of diagnosed thyroid cancer increased fifteen-fold over the following decade, making South Korea the world leader in thyroid cancer diagnosis rates.

But the death rate from thyroid cancer remained unchanged.

Researchers H. Gilbert Welch and Hyeong Sik Ahn published a 2014 analysis in the New England Journal of Medicine demonstrating that approximately 90% of the additional thyroid cancers detected in South Korea represented overdiagnosis. Ultrasound was finding tiny papillary microcarcinomas -- cancers smaller than 1 centimeter -- that autopsy studies had long shown are present in up to 36% of adults who die of unrelated causes (Harach et al., 1985). These cancers were always there; the technology simply made them visible.

The patients whose cancers were "found" then underwent treatment: thyroidectomy (with risks of permanent vocal cord damage and hypoparathyroidism), radioiodine ablation (with associated radiation exposure), and lifelong thyroid hormone replacement. They bore surgical scars, swallowed daily medication, and lived with the psychological burden of having been "cancer patients" -- for a condition that posed no actual threat.

Overdiagnosis in Breast and Prostate Cancer

Similar patterns have been documented in prostate-specific antigen (PSA) testing for prostate cancer and in mammography for breast cancer. A 2012 Cochrane Review of PSA screening estimated that for every 1,000 men screened, 0 to 1 deaths from prostate cancer would be prevented, while 29 to 44 men would receive a diagnosis leading to treatment with significant side effects -- incontinence, impotence, and bowel dysfunction.

For breast cancer, a 2012 analysis by Archie Bleyer and H. Gilbert Welch in the New England Journal of Medicine estimated that mammography screening had led to the overdiagnosis of approximately 1.3 million women in the United States over the preceding three decades. These women underwent surgery, radiation, chemotherapy, or hormonal therapy for cancers that would not have threatened their lives.

The fundamental challenge of overdiagnosis is that it is invisible at the individual level. For any single patient, you cannot know whether their detected cancer would have progressed or remained indolent. The harm can only be quantified at the population level, by comparing diagnosis rates with mortality rates over time.

Defensive Medicine: The Cobra Effect of Malpractice Liability

Defensive medicine -- ordering tests, procedures, and referrals not because they are clinically indicated but to reduce the physician's exposure to malpractice liability -- is a less-discussed but pervasive source of iatrogenic harm.

A 2010 survey published in JAMA Internal Medicine (originally Archives of Internal Medicine) by Tara Bishop and colleagues found that 91% of physicians reported practicing some form of defensive medicine, with 43% reporting that they ordered imaging studies they considered unnecessary. A 2018 study in the Journal of the American Medical Association estimated the annual cost of defensive medicine in the U.S. at between $75 billion and $210 billion, depending on methodology.

Beyond cost, defensive medicine exposes patients to real harm: unnecessary CT scans deliver ionizing radiation that accumulates cancer risk over a lifetime. Unnecessary blood tests generate false positives that trigger further unnecessary workup. Unnecessary surgical biopsies carry infection and complication risks. Each unnecessary test also increases the probability of an anchoring bias in subsequent clinical reasoning, where physicians fixate on incidental findings rather than the presenting problem.

The cobra effect is precise: a legal system designed to protect patients from physician negligence has created incentive structures that generate a different, diffuse form of harm -- not through carelessness, but through excess.

The Precautionary Principle and Primum Non Nocere

Two ethical frameworks are central to the iatrogenesis discussion.

Primum non nocere -- "first, do no harm" -- is frequently attributed to Hippocrates, though the exact phrase does not appear in the Hippocratic Corpus. The earliest documented use in English medical literature is from Thomas Inman in 1860. Regardless of its origins, the principle expresses a clear priority: before attempting to help, ensure you are not hurting. It does not counsel inaction. It counsels deliberateness -- the discipline to ask "what harm might this cause?" with the same rigor applied to "what benefit might this provide?"

The precautionary principle goes further: in the face of scientific uncertainty about potential harm, the burden of proof lies with those proposing the intervention to demonstrate safety, not with those urging caution. This principle underlies pharmaceutical regulation (drugs must prove safety and efficacy before approval) and is increasingly invoked in debates about nudge theory and public health interventions where benefits are population-level but harms fall on individuals.

Active Surveillance: When Doing Nothing Is the Evidence-Based Choice

One of the most important developments in modern medicine is the growing acceptance of active surveillance -- the deliberate decision to monitor a condition rather than treat it immediately. Active surveillance has become standard of care for low-risk prostate cancer (Gleason score 6), small thyroid nodules, and certain other conditions where the risks of treatment exceed the risks of the disease.

This represents a profound institutional shift. For decades, the medical culture defaulted to intervention: if we can detect it, treat it. Active surveillance acknowledges that watchful waiting is itself a medical decision, not a failure to act. Studies following men with low-risk prostate cancer on active surveillance have shown 10-year cancer-specific survival rates exceeding 99% (Klotz et al., Journal of Clinical Oncology, 2015), comparable to immediate treatment but without the side effects.

The psychological difficulty is real. Both patients and physicians feel the pull toward action when a diagnosis exists. The word "cancer" triggers a loss aversion response so powerful that many patients choose aggressive treatment even when shown data demonstrating that surveillance produces equivalent outcomes. Overcoming this requires not just better evidence but better communication -- and an understanding of the framing effects that shape how medical information is perceived.

What Responsible Medicine Looks Like

None of this is an argument for medical nihilism. Modern medicine has doubled human life expectancy, eradicated smallpox, made childbirth survivable, and turned many cancers from death sentences into chronic conditions. The argument is not against medicine. It is against unexamined medicine -- care delivered without rigorous accounting of both benefits and costs.

Evidence-based medicine (EBM), formalized by David Sackett and colleagues at McMaster University in the 1990s, represents the systematic attempt to ground clinical decisions in the best available evidence rather than tradition, authority, or commercial pressure. The Cochrane Collaboration, founded in 1993, has produced thousands of systematic reviews that have repeatedly identified medical practices adopted without sufficient evidence -- and subsequently found to be ineffective or harmful.

Shared decision-making involves presenting patients with genuine, comprehensible information about the probabilities of benefit and harm from available options -- including the option of no treatment -- and respecting patient preferences in the final decision. A 2017 Cochrane Review of shared decision-making interventions found that patients who participate in shared decision-making are more knowledgeable, more accurate in their risk perceptions, and more likely to choose less invasive options when appropriate.

Antibiotic stewardship programs -- which restrict the use of broad-spectrum antibiotics, require culture results before prescribing, and track institutional resistance patterns -- have been shown to reduce antibiotic use by 20-30% without adverse patient outcomes (Davey et al., Cochrane Database of Systematic Reviews, 2017). They represent exactly the kind of collective restraint needed to address population-level iatrogenesis.

Post-market surveillance of drugs and devices, with mandatory adverse event reporting and genuine willingness to withdraw approvals when safety signals emerge, addresses the gap between controlled clinical trial populations and the vastly more diverse real-world patient population.

The Systems Perspective: Why Iatrogenesis Persists

Understanding why iatrogenesis is so persistent requires looking beyond individual errors to the system-level incentives that produce them. Several structural factors drive iatrogenic harm:

Fee-for-service payment rewards volume over value. A physician who orders ten tests earns more than one who orders two, regardless of which approach produces better outcomes. The Affordable Care Act's push toward value-based payment models represents an attempt to realign these incentives, but fee-for-service remains dominant in many settings.

Pharmaceutical marketing shapes prescribing behavior in ways that do not always align with patient interest. The U.S. and New Zealand are the only two countries that permit direct-to-consumer pharmaceutical advertising. In 2022, the pharmaceutical industry spent an estimated $6.58 billion on advertising in the U.S. alone (Kantar Media). Physicians receive an average of $2,000-$3,000 per year in meals, travel, and consulting fees from pharmaceutical companies (Open Payments data, CMS).

Screening culture creates a ratchet effect: once a screening test exists and is marketed to the public, it becomes politically and culturally difficult to recommend against it -- even when evidence shows the harms of screening exceed the benefits. The U.S. Preventive Services Task Force has faced significant public backlash when recommending less frequent mammography or against routine PSA screening, despite basing those recommendations on rigorous evidence review.

Malpractice liability, as discussed above, pushes physicians toward overtesting and overtreatment as a legal shield.

The result is a system where the default is action -- more tests, more diagnoses, more treatments -- and where restraint requires swimming against powerful currents of financial incentive, cultural expectation, legal risk, and institutional momentum.

Conclusion: The Ancient Injunction Still Holds

The cobra effect appears in healthcare as reliably as in colonial governance or financial regulation: a well-intentioned intervention, poorly calibrated to the complexity of the system it operates in, creates harms that rival or exceed the harms it was designed to address. The opioid crisis was driven by prescription pads. Antibiotic resistance is driven by antibiotic prescriptions. Overdiagnosis is driven by screening programs.

Iatrogenesis is not an indictment of physicians, who are generally well-intentioned and often working under constraints they did not create. It is an indictment of systems -- pharmaceutical incentives, liability structures, screening culture, payment models, and a deep cultural bias toward action -- that push medicine toward doing more without systematically asking whether more is better.

The ancient injunction remains the clearest guide. First, do no harm. Not a prohibition on action, but a demand for honesty about what actions cost -- and the cognitive humility to recognize that good intentions, without rigorous measurement, are not enough.

---

References and Further Reading

1. Illich, I. Medical Nemesis: The Expropriation of Health. Pantheon Books, 1976.
2. Kohn, L.T., Corrigan, J.M., & Donaldson, M.S. (Eds.). To Err is Human: Building a Safer Health System. Institute of Medicine, National Academies Press, 1999. https://nap.nationalacademies.org/catalog/9728
3. James, J.T. "A New, Evidence-Based Estimate of Patient Harms Associated with Hospital Care." Journal of Patient Safety 9, no. 3 (2013): 122-128.
4. Makary, M.A. & Daniel, M. "Medical Error -- The Third Leading Cause of Death in the US." BMJ 353 (2016): i2139. https://doi.org/10.1136/bmj.i2139
5. Murray, C.J. et al. "Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis." The Lancet 399, no. 10325 (2022): 629-655.
6. O'Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Review on Antimicrobial Resistance, 2016. https://amr-review.org/Publications.html
7. Welch, H.G. & Ahn, H.S. "The Biomedical Arms Race and the Growth of Cancer in South Korea." New England Journal of Medicine 371 (2014): 765-767.
8. Bleyer, A. & Welch, H.G. "Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence." New England Journal of Medicine 367 (2012): 1998-2005.
9. Lembke, A. Drug Dealer, MD: How Doctors Were Duped, Patients Got Hooked, and Why It's So Hard to Stop. Johns Hopkins University Press, 2016.
10. Welch, H.G., Schwartz, L.M., & Woloshin, S. Overdiagnosed: Making People Sick in the Pursuit of Health. Beacon Press, 2011.
11. Sackett, D.L. et al. Evidence-Based Medicine: How to Practice and Teach EBM. Churchill Livingstone, 2000.
12. Bishop, T.F. et al. "Physicians' Views on Defensive Medicine: A National Survey." Archives of Internal Medicine 170, no. 12 (2010): 1081-1083.
13. Klotz, L. et al. "Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer." Journal of Clinical Oncology 33, no. 3 (2015): 272-277.
14. Centers for Disease Control and Prevention. "Understanding the Epidemic: Opioid Overdose." https://www.cdc.gov/opioids/basics/epidemic.html
15. Davey, P. et al. "Interventions to Improve Antibiotic Prescribing Practices for Hospital Inpatients." Cochrane Database of Systematic Reviews 2 (2017).

Frequently Asked Questions

What is iatrogenesis?

Iatrogenesis refers to harm caused by medical examination, treatment, or advice. The term comes from the Greek 'iatros' (physician) and 'genesis' (origin). Iatrogenic harm ranges from individual adverse drug reactions to population-level crises like the opioid epidemic, which was substantially driven by physician prescribing of OxyContin and other opioids in the 1990s and 2000s.

Who introduced the concept of iatrogenesis as a social critique?

Ivan Illich, the Austrian philosopher and social critic, gave iatrogenesis its broadest formulation in his 1976 book 'Medical Nemesis.' Illich argued that modern medicine had become 'a major threat to health' through clinical iatrogenesis (direct harm from treatment), social iatrogenesis (medicalizing normal life), and structural iatrogenesis (undermining people's capacity to manage their own health).

How does antibiotic resistance represent a form of iatrogenesis?

Antibiotic resistance is an iatrogenic problem at the population level: by using antibiotics to treat individual patients (often for viral infections where they provide no benefit), medicine has created the conditions for bacteria to evolve resistance. The World Health Organization estimates that antimicrobial resistance causes 700,000 deaths annually, a figure projected to rise to 10 million per year by 2050 if current trends continue.

What is overdiagnosis and how does it cause harm?

Overdiagnosis occurs when a condition is detected through screening or testing that would never have caused symptoms or harm in the patient's lifetime. The harms flow from subsequent treatment: surgery, chemotherapy, and radiation for cancers that were never destined to progress. Studies of thyroid cancer screening in South Korea and breast cancer screening in multiple countries show significant rates of overdiagnosis, leading to unnecessary interventions with real side effects.

What is the precautionary principle in medicine?

The medical precautionary principle holds that when an action carries risk of harm, the burden of proof lies with those proposing the action to demonstrate safety and benefit, not with those urging caution. It is related to the ancient maxim 'primum non nocere' (first, do no harm), which frames the physician's primary obligation as avoiding harm rather than merely attempting to benefit. Both principles counsel caution in the face of uncertainty.